Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?
|dc.identifier.citation||Pors K and Moreb JS (2014) Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development? Drug Discovery Today. 19(12): 1953-1963.|
|dc.description.abstract||Aldehyde dehydrogenases (ALDHs) belong to a superfamily of 19 isozymes that are known to participate in many physiologically important biosynthetic processes including detoxification of specific endogenous and exogenous aldehyde substrates. The high expression levels of an emerging number of ALDHs in various cancer tissues suggest that these enzymes have pivotal roles in cancer cell survival and progression. Mapping out the heterogeneity of tumours and their cancer stem cell (CSC) component will be key to successful design of strategies involving therapeutics that are targeted against specific ALDH isozymes. This review summarises recent progress in ALDH-focused cancer research and discovery of small-molecule-based inhibitors.|
|dc.subject||Animals; Antineoplastic agents; Drug discovery; Biomarkers; Humans; Isoenzymes; Antagonists;Neoplasms; Neoplastic stem cells; Aldehyde dehydrogenase|
|dc.title||Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?|
|dc.type.version||No full-text available in the repository|